DGAP-News

WILEX AG: Subsidiary Heidelberg Pharma and Nordic Nanovector Enter into Collaboration to Develop Novel Antibody Drug Conjugates (ADC)

DGAP-News: WILEX AG / Key word(s): Alliance
WILEX AG: Subsidiary Heidelberg Pharma and Nordic Nanovector Enter into
Collaboration to Develop Novel Antibody Drug Conjugates (ADC)

26.10.2016 / 07:00
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PRESS RELEASE

WILEX AG: Subsidiary Heidelberg Pharma and Nordic Nanovector Enter into
Collaboration to Develop Novel Antibody Drug Conjugates (ADC)

Munich, Germany, 26 October 2016 - WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE)
today announced that its subsidiary Heidelberg Pharma GmbH, Ladenburg,
Germany, entered into a research collaboration with Nordic Nanovector ASA,
Oslo, Norway (Ticker: NANO), a biotech company focusing on the development
and commercialization of novel targeted therapeutics in hematology and
oncology. The collaboration aims at developing novel antibody drug
conjugates (ADCs) to treat leukemias. Leukemias are orphan diseases with a
significant unmet medical need, applicable indications representing a
growing market worth over USD 5 billion by 2020 .

Professor Dr Andreas Pahl, Head of Research & Development and member of the
Management Board of WILEX and Heidelberg Pharma, commented: "The project
extends our ADC portfolio to additional hematological cancers. Nordic
Nanovector has an established chemistry, manufacturing, and controls (CMC)
process for their antibody which will speed up processes and reduce the
development costs of the ADCs."

Jostein Dahle, Nordic Nanovector's Chief Scientific Officer, added: "We are
pleased to further expand our R&D activities into the ADC area with
Heidelberg Pharma. During the past year, we have made important steps to
execute our strategy designed to build a pipeline of innovative antibody-
radionuclide conjugates (ARCs) and ADCs that combine our expertise and
platform with complementary technologies from expert partners."

About WILEX and Heidelberg Pharma's proprietary ATAC technology

WILEX AG is a biopharmaceutical company based in Munich, Germany, that
serves as a parent and holding company. The Company's research and
development work is conducted by its subsidiary, Heidelberg Pharma GmbH in
Ladenburg. Heidelberg Pharma is focused on developing an innovative ADC
technology platform based on the compound Amanitin (ATAC technology) and
also provides preclinical drug research and development services.

Antibody drug conjugates (ADCs) combine the high affinity and specificity
of antibodies with the potency of cytotoxic small molecules for the
treatment of cancer and inflammatory diseases. ATACs are ADCs that are